GHRP-6 GR6
GHS-R1a agonist
Synthetic hexapeptide ghrelin-receptor (GHS-R1a) agonist that stimulates pituitary growth hormone release and food intake.
Evidence level. Published human clinical data exists, from trials or approved use. About the badges
- Class
- GHS-R1a agonist
- Category
- Growth Hormone Axis
- Type
- Single compound
- Abbreviation
- GR6
- Development and regulatory status
- Not approved; investigational research peptide
What researchers study
Synthetic hexapeptide ghrelin-receptor (GHS-R1a) agonist, one of the earliest growth hormone-releasing peptides. It stimulates pituitary GH release and food intake and has been examined for tissue-protective effects in animal models.
Research areas
- Ghrelin-receptor, GH release and appetite-pathway studies
- Hypothalamic feeding-circuit activation in mice
- Cardiac and lung injury models in rodents
- Nicotine-withdrawal behaviour in rats
Reported findings
Summaries of published results. Each one is tagged with the type of study behind it. They describe research outcomes and are not claims about any product. Why study type matters.
- review
Systemic GHRP-6 is described as stimulating GH release in humans and rats, as background to a 2025 mouse study
- rodent
In mice, GHRP-6 increased food intake through greater meal frequency and size and raised neuronal activation in the hypothalamic arcuate nucleus
- rodent
A 2026 rat study of coronary ligation reported GHRP-6 was associated with reduced post-infarct ventricular remodelling and systolic dysfunction
Studied alongside
Compounds that appear together in research because their mechanisms complement each other, or as comparators. The reasons given are research reasoning, not recommendations for use.
- GHRP-6 Acetateacetate salt form of the same peptide
- GHRP-2related ghrelin-receptor agonist compared in appetite and GH studies
- CJC-1295 (no DAC)GHRH analogue that synergises with ghrelin-receptor agonists
